Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































Vermont First in the Nation to Approve Rx Drug Importation from Canada
/in Policy Vermont Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersVermont is the first state in the nation to approve importation of less-costly prescription drugs from Canada. For the first time in the United States, obtaining low-cost prescription drugs from Canada is one step closer to reality today following the Vermont state legislature’s landmark enactment of S.175. Vermont Gov. Philip Scott signed the bill into law on […]
While the Administration Mulls How to Curb Prescription Costs, State Legislatures Take the Lead
/in Policy Blogs Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersAs the country awaits the Administration’s plan to curb Rx drug costs, states take the lead, proposing and passing legislation to lower costs, despite industry opposition. As we await the details of President Trump’s proposals to curb escalating drug prices, states are continuing to push legislation to lower the cost of prescription drugs, despite the strong […]
States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing
/in Policy Blogs, Charts Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersSeveral states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. These laws are an important first step to shine a light on why drug prices are rapidly climbing. To address a problem, state health policymakers need to understand it, but transparency laws don’t yet give […]
Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation
/in Policy Reports Administrative Actions, Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Jane HorvathAs the number of state bills to rein in prescription drug prices grows beyond 150 nationwide in 2018, the first generation of several state laws passed last year are now before the courts. The pharmaceutical industry has consistently challenged drug cost transparency and price gouging legislation passed in 2017 in federal courts. How well these […]
An Oregon State Lawmaker Crafts a Winning Strategy for Transparency Legislation
/in Policy Oregon Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffLast week, Oregon Gov. Kate Brown signed a drug cost transparency bill into law that requires drug makers to report the reasons behind dramatic drug price increases. The bill’s leading advocate and architect, state Rep. Robert Nosse, D-Portland, worked for nearly three years to create a prescription cost containment bill that would win bipartisan support […]
Can States Regulate Drug Costs without Violating Patent Law? Yes, Here’s Why
/in Policy Blogs Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Legal Resources, Prescription Drug Pricing, State Rx Legislative Action /by Jane HorvathWhen states pass laws that enable them to regulate prescription drug costs or mandate drug pricing transparency, the pharmaceutical industry always fires back with lawsuits claiming the states are violating federal law. In 2017, the industry sued every state that enacted drug cost containment legislation claiming they had violated myriad federal laws, including the Patent […]
How States Can Contain Rx Drug Costs without Violating Federal Patent Law
/in Policy Reports Administrative Actions, Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffThis National Academy for State Health Policy white paper, States’ Rights: A Patent Law Analysis of NASHP Rate-Setting Model Act by experts at the University of California Hastings College of the Law, explores why state drug rate-setting legislation and other cost containment approaches do not violate federal patent law and can withstand legal challenges. This […]
How the Federal Government Can Help States Address Rising Prescription Drug Costs
/in Policy Blogs Prescription Drug Pricing /by NASHP StaffState Medicaid programs, which face rapidly rising drug costs, have few bargaining chips to use when negotiating lower drug costs, due in part to decades-old federal rules that limit their bargaining power. NASHP, with support of The Commonwealth Fund, recently sat down with state and federal policymakers to identify policy and rule changes that could […]
Four More States Submit Bills to Import Prescription Drugs from Canada
/in Policy Colorado, Missouri, Oklahoma, Utah, Vermont, West Virginia Blogs Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersAs states pursue a wide range of legislation to address rising drug costs, four more states have joined Utah and Vermont to introduce bills to import prescription drugs from Canada through a state-run, wholesale operation. This market-based approach to providing more affordable medicines from Canada, where prescription drugs cost on average 30 percent less than […]
Bracing for an Uncertain 2018, States Can Apply the Flexibility and Innovation Learned in 2017
/in Policy Blogs Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Medicaid Managed Care, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, Quality and Measurement, State Rx Legislative Action, Value-Based Purchasing /by Anita CardwellThe federal political and funding uncertainties that affected state health insurance coverage in 2017, including the potential repeal of the Affordable Care Act (ACA), are expected to reverberate through 2018. But this year, state health care policymakers have some lessons learned about the value of state flexibility and innovation as they navigate another tumultuous year. […]